Estimation of warfarin maintenance dose based on VKORC1 (-1639 G>A) and CYP2C9 genotypes.

No abstract is available for this paper.

• Publication year

  2007

• Venue

  Clinical Chemistry

• Publication date

  2007-07-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1373/CLINCHEM.2006.078139PMID 17510308
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Individualizing warfarin therapy.

  2007cited by this paper
• Genotypes of vitamin K epoxide reductase, gamma-glutamyl carboxylase, and cytochrome P450 2C9 as determinants of daily warfarin dose in Japanese patients.

  2007cited by this paper
• Simultaneous determination of 7 N-acetyltransferase-2 single-nucleotide variations by allele-specific primer extension assay.

  2006cited by this paper
• Combined genetic profiles of components and regulators of the vitamin K-dependent γ-carboxylation system affect individual sensitivity to warfarin

  2006cited by this paper
• Association of warfarin dose with genes involved in its action and metabolism

  2006cited by this paper
• Different contributions of polymorphisms in VKORC1 and CYP2C9 to intra- and inter-population differences in maintenance dose of warfarin in Japanese, Caucasians and African-Americans

  2006cited by this paper
• A warfarin‐dosing model in Asians that uses single‐nucleotide polymorphisms in vitamin K epoxide reductase complex and cytochrome P450 2C9

  2006cited by this paper
• Common VKORC1 and GGCX polymorphisms associated with warfarin dose

  2005cited by this paper
• Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose.

  2005cited by this paper
• Cytochrome P450 2C9 (CYP2C9) and vitamin K epoxide reductase (VKORC1) genotypes as determinants of acenocoumarol sensitivity.

  2005cited by this paper
• A novel functional VKORC1 promoter polymorphism is associated with inter-individual and inter-ethnic differences in warfarin sensitivity.

  2005cited by this paper
• A vitamin K epoxide reductase complex subunit‐1 (VKORC1) mutation in a patient with vitamin K antagonist resistance

  2005cited by this paper
• The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen.

  2005cited by this paper
• Patients with an ApoE ϵ4 allele require lower doses of coumarin anticoagulants

  2005cited by this paper
• Bleeding complications to long-term oral anticoagulant therapy

  2005cited by this paper
• Analytical validation of the tag-it high-throughput microsphere-based universal array genotyping platform: application to the multiplex detection of a panel of thrombophilia-associated single-nucleotide polymorphisms.

  2004cited by this paper
• Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2

  2004cited by this paper
• Pharmacodynamic resistance to warfarin associated with a Val66Met substitution in vitamin K epoxide reductase complex subunit 1

  2004cited by this paper
• Association of pharmacokinetic (CYP2C9) and pharmacodynamic (factors II, VII, IX, and X; proteins S and C; and gamma-glutamyl carboxylase) gene variants with warfarin sensitivity.

  2003cited by this paper
• Warfarin Dose Adjustments Based on CYP2C9 Genetic Polymorphisms

  2002cited by this paper
• Cytochrome P450 2C9 polymorphisms: a comprehensive review of the in-vitro and human data.

  2002cited by this paper
• Statistics with confidence

  2000cited by this paper
• Chiral phase analysis of warfarin enantiomers in patient plasma in relation to CYP2C9 genotype.

  1998cited by this paper
• Comparisons between in-vitro and in-vivo metabolism of (S)-warfarin: catalytic activities of cDNA-expressed CYP2C9, its Leu359 variant and their mixture versus unbound clearance in patients with the corresponding CYP2C9 genotypes.

  1998cited by this paper
• Impaired (S)-warfarin metabolism catalysed by the R144C allelic variant of CYP2C9.

  1994cited by this paper
• Hereditary warfarin resistance.

  1994cited by this paper
• High clearance of (S)-warfarin in a warfarin-resistant subject.

  1993cited by this paper
• Factors affecting the maintenance dose of warfarin.

  1992cited by this paper
• Familial warfarin resistance in a black child.

  1986cited by this paper
• Hereditary warfarin resistance. Investigation of a rare phenomenon.

  1985cited by this paper

• Clinical, genetic, and nutritional determinants of INR: role of plasma warfarin and hydroxylated metabolite levels in anticoagulated Mexican patients.

  2025cites this paper
• Semi-empirical Anticoagulation Model (SAM): Dose prediction during warfarin therapy

  2025cites this paper
• Interaction of the lysozyme with anticoagulant drug warfarin: Spectroscopic and computational analyses

  2024cites this paper
• Association between CYP2C9 and VKORC1 genetic polymorphisms and efficacy and safety of warfarin in Chinese patients

  2024cites this paper
• A Systematic Review of Polygenic Models for Predicting Drug Outcomes

  2022cites this paper
• Modulation of Warfarin Sodium into Warfarin Potassium for Patients with Hypertension

  2022cites this paper
• NGHIÊN CỨU VỀ TỔ HỢP GEN VKORC1 VÀ CYP2C9 TRÊN BỆNH NHÂN HUYẾT KHỐI TĨNH MẠCH NÃO ĐIỀU TRỊ WARFARIN

  2021cites this paper
• An Adapted Neural-Fuzzy Inference System Model Using Preprocessed Balance Data to Improve the Predictive Accuracy of Warfarin Maintenance Dosing in Patients After Heart Valve Replacement

  2021cites this paper
• Warfarin Dose in Iranian Adult Patients with an Artificial Heart Valve by Using Artificial Neural Networks

  2021cites this paper
• –1639G>A and are the major genetic predictors of phenprocoumon dose requirement

  2020cites this paper
• Pharmacogenetic testing: 5 Questions

  2020cites this paper
• The Contribution of VKORC1 and CYP2C9 Genetic Polymorphisms and Patients’ Demographic Characteristics with Warfarin Maintenance Doses: A Suggested Warfarin Dosing Algorithm

  2020cites this paper
• Farmacogenômica e Doença Cardiovascular: Onde Estamos e Para Onde Vamos

  2020cites this paper
• Current state and future perspective of cardiovascular medicines derived from natural products.

  2020cites this paper
• Therapeutic strategies for thrombosis: new targets and approaches

  2020cites this paper
• Pharmacogenomics and personalized medicine in the treatment of human diseases

  2020cites this paper
• Поширеність алельних варіантів генів VKORC1, CYP2C9 CYP4F2 області

  2019cites this paper
• FEP Medical Policy Manual FEP 2.04.48 Genotype-Guided Warfarin Dosing

  2019cites this paper
• Clinical Practice Considerations

  2019cites this paper
• The Impact of CYP2C9 and VKORC1 Polymorphism in Patient’s Response to Warfarin and Acenocoumarol

  2019cites this paper
• Cytochrome P 450 Genotyping Policy Number : 2 . 04 . 38 Last Review : 3 / 2019 Origination : 3 / 2017 Next Review : 3 / 2020 Policy

  2019cites this paper
• Genetic risk assessment towards warfarin application: Saudi Arabia study with a potential to predict and prevent side effects

  2019influential citation
• Dosing of Warfarin in Iranian Adult Patients with An Artificial Heart Valve Using Artificial Neural Networks

  2018cites this paper
• Effects of safflower injection on the pharmacodynamics and pharmacokinetics of warfarin in rats

  2018cites this paper
• The dose individualisation of oral anticoagulants

  2018influential citation
• Relationship Between Pharmacokinetics and Pharmacogenomics and Its Impact on Drug Choice and Dose Regimens

  2018cites this paper
• Prevalence and genotype distribution of human papillomavirus infection among women in northeastern Guangdong Province of China

  2018cites this paper
• ADME Processes in Pharmaceutical Sciences

  2018cites this paper
• PHARMACOGENETICS OF ANTITHROMBOTIC DRUGS: STATUS UPDATE ON THE PROBLEM

  2018cites this paper
• Genotype-guided warfarin dosing

  2018cites this paper
• Pharmacogenetics of warfarin dosing in patients of African and European ancestry.

  2018cites this paper
• Фармакогенетика антитромботических препаратов: современное состояние проблемы

  2018cites this paper
• Missense mutation of VKORC1 leads to medial arterial calcification in rats

  2018cites this paper
• The Effect of Demographic Factors and VKORC1 1639 G>A Genotypes on Estimated Warfarin Maintenance Dose in Iranian Patients Under Warfarin Therapy

  2018cites this paper
• Personalized Anticoagulation: Optimizing Warfarin Management Using Genetics and Simulated Clinical Trials

  2017cites this paper
• Frequency of Common VKORC1 Polymorphisms and Their Impact on Warfarin Dose Requirement in Pakistani Population

  2017cites this paper
• The VKORC1 and CYP2C9 genotypes significantly effect Vitamin K antagonist dosing only in patients over the age of 20years.

  2017cites this paper
• Pharmacogenetics-based warfarin dose prediction algorithm for patients with heart valve replacement in Southeast China

  2017cites this paper
• Genetic Testing for Warfarin Dose Policy # 00245

  2017cites this paper
• VKORC1-1639 G>A Polymorphism and the Risk of Non-Variceal Upper Gastrointestinal Bleeding.

  2017cites this paper
• Impact of VKORC1 gene polymorphisms on warfarin maintenance dosage: A novel systematic review and meta-analysis of 53 studies.

  2017cites this paper
• Warfarin Dosing Algorithms Underpredict Dose Requirements in Patients Requiring ≥7 mg Daily: A Systematic Review and Meta‐analysis

  2017cites this paper
• Cytochrome p 450 Genotyping 1 Cytochrome p 450 Genotyping Policy

  2017cites this paper
• Pharmacogenomics of CYP2C9: Functional and Clinical Considerations†

  2017cites this paper
• Genotype-based anticoagulant therapy with warfarin for atrial fibrillation

  2017cites this paper
• Pharmacogenetic Testing

  2017cites this paper
• Hematoma Expansion Following Intracerebral Hemorrhage: Mechanisms Targeting the Coagulation Cascade and Platelet Activation.

  2017cites this paper
• Development of neuro-fuzzy model to explore gene-nutrient interactions modulating warfarin dose requirement.

  2016cites this paper
• The Pharmacist's Perspective on Pharmacogenetics Implementation.

  2016cites this paper
• Development and Comparison of Warfarin Dosing Algorithms in Stroke Patients

  2016cites this paper
• VKORC1 and CYP2C9 genotypes in Egyptian patients with warfarin resistance

  2016cites this paper
• Warfarin Pharmacogenetics Reevaluated:  Subgroup Analysis Reveals a Likely Underestimation of the Maximum Pharmacogenetic Benefit by Clinical Trials.

  2016cites this paper
• The Impact of Genetic and Non-Genetic Factors on Warfarin Dose Prediction in MENA Region: A Systematic Review

  2016cites this paper
• Association of Genetic Polymorphisms of CYP2C9 and VKORC1 with Bleeding Following Warfarin: A Case-Control Study.

  2016cites this paper
• Artificial neural network-based pharmacogenomic algorithm for warfarin dose optimization.

  2016cites this paper
• Impact of the CYP4F2 gene polymorphisms on the warfarin maintenance dose: A systematic review and meta-analysis.

  2016cites this paper
• VKORC1 -1639G/A and 1173 C/T Genetic Polymorphisms Influence Individual Differences in Warfarin Maintenance Dose

  2015cites this paper
• Validation of warfarin pharmacogenetic algorithms in 586 Han Chinese patients.

  2015cites this paper
• Rationale for CYP2C9/ VKORC1 Genotyping of Patients Prescribed Warfarin Warfarin Pharmacogenetics

  2015cites this paper
• Development of a pharmacogenetic-based warfarin dosing algorithm and its performance in Brazilian patients: highlighting the importance of population-specific calibration.

  2015cites this paper
• Recommendations for the frequency of ordering laboratory testing

  2015cites this paper
• VKORC1 gene polymorphisms and adverse events in Croatian patients on warfarin therapy.

  2015cites this paper
• Research progress in CYP2C9 and VKORC1 gene polymorphism and individualized warfarin therapeutic regimen

  2015cites this paper
• Poljaković Z. (2014) Prevalence of genetic polymorphisms of CYP2C9 and VKORC1 - implications for warfarin management and outcome in Croatian patients with acute stroke

  2015cites this paper
• Development and Comparison of a Warfarin-Dosing Algorithm in Chinese Han Patients with Atrial Fibrillation

  2015cites this paper
• Pharmacogenetic-guided algorithms to estimate personalized dose or individual responses to anti-thrombotic drugs

  2015cites this paper
• Ambulatory Warfarin Management

  2015cites this paper
• The effect of VKORC1 (-1639 G>A) gene polymorphism and its related clotting factor IIa and Xa on warfarin therapy in patients with atrial fibrillation: a multi-ethnic Sarawak population study

  2015cites this paper
• Effect of VKORC 1-1639 G > A polymorphism on warfarin response in east of Turkey Türkiye

  2015cites this paper
• Clinical Application of Genotype-guided Dosing of Warfarin in Patients with Acute Stroke.

  2015cites this paper
• Effect of CYP2C9–VKORC1 interaction on warfarin stable dosage and its predictive algorithm

  2015cites this paper
• Warfarin Metabolites in Patients Following Cardiac Valve Implantation: A Contribution of Clinical and Genetic Factors

  2015cites this paper
• PGWD: Integrating Personal Genome for Warfarin Dosing

  2015cites this paper
• Comparison of Nine Statistical Model Based Warfarin Pharmacogenetic Dosing Algorithms Using the Racially Diverse International Warfarin Pharmacogenetic Consortium Cohort Database

  2015cites this paper
• A New Nested Allele-Specific Multiplex Polymerase Chain Reaction Method for Haplotyping of VKORC1 Gene to Predict Warfarin Sensitivity

  2014cites this paper
• A Proposal for an Individualized Pharmacogenetic-Guided Warfarin Dosage Regimen for Puerto Rican Patients Commencing Anticoagulation Therapy

  2014cites this paper
• A Review of A Priori Regression Models for Warfarin Maintenance Dose Prediction

  2014cites this paper
• Pharmacogenomics of Warfarin

  2014cites this paper
• Case report: dose adjustment of warfarin using genetic information and plasma concentration monitoring

  2014cites this paper
• MP- 2.306 Genetic Testing for Warfarin Dose MP-2.309 KIF6 Genotyping for Predicting Cardiovascular Risk and/or Effectiveness of Statin Therapy MP-2.311 Genotyping for 9p21 Single Nucleotide Polymorphisms to Predict Risk of Cardiovascular Disease or Aneurysm MP-2.218 Pharmacogenic and Metabolite Mark

  2014cites this paper
• Study Of Genetic And Pharmacokinetic Issues Related To Efficacy And Toxicity Of Warfarin In Pakistani Subjects

  2014cites this paper
• Cytochrome P450 Genotyping

  2014cites this paper
• Cytochrome p450 Genotyping - 04/14

  2014cites this paper
• Cytochrome p 450 Genotyping Policy # 00169

  2014cites this paper
• Original article The impact of VKORC1-1639G > A genetic polymorphism upon warfarin dose requirement in different ethnic populations

  2014cites this paper
• Prevalence of genetic polymorphisms of CYP2C9 and VKORC1 - implications for warfarin management and outcome in Croatian patients with acute stroke.

  2014cites this paper
• The impact of VKORC1-1639G > A genetic polymorphism upon warfarin dose requirement in different ethnic populations

  2014cites this paper
• Empfehlungen zur Häufigkeit der Anforderung von Laboruntersuchungen

  2014cites this paper
• VKORC1 and CYP2C9 Genotype Variations in Relation to Warfarin Dosing in Korean Stroke Patients

  2013cites this paper
• Effect of CYP2C9, VKORC1, CYP4F2 and GGCX genetic variants on warfarin maintenance dose and explicating a new pharmacogenetic algorithm in South Indian population

  2013cites this paper
• Vitamin K epoxide reductase complex 1 (VKORC1) gene polymorphisms in population of Eastern Croatia.

  2013cites this paper
• Pharmacogenomics of Anti-platelet and Anti-coagulation Therapy

  2013cites this paper
• Adherence and variability in warfarin dose requirements: assessment in a prospective cohort.

  2013cites this paper
• Genetic and Clinical Determinants Influencing Warfarin Dosing in Children With Heart Disease

  2013cites this paper
• Effect of CYP2C9 and VKORC1 genetic variations on warfarin dose requirements in Indian patients

  2013cites this paper
• Ugotavljanje VKORC1 polimorfizma: Primerjava metod verižne reakcije s polimerazo/ polimorfizma dolžin restrikcijskih fragmentov (PCR + RFLP) z alelno specifično verižno reakcijo s polimerazo Detection of vkorc1 polymorphism: comparison of polymerase chain reaction/restriction fragment length pol

  2013cites this paper
• Inter and intra ethnic variation of vitamin K epoxide reductase complex and cytochrome P450 4F2 genetic polymorphisms and their prevalence in South Indian population

  2013cites this paper
• Repeated bleeding complications during therapy with vitamin K antagonists in a patient with the VKORC1*2A and the CYP2C9*3/*3 alleles: genetic testing to support switching to new oral anticoagulants.

  2013cites this paper
• Reinforcement of Appropriate Use of Drugs by Developing Simple Genotyping Methods and Their Clinical Application

  2013cites this paper
• The pharmacokinetics and pharmacodynamics of single dose (R)- and (S)-warfarin administered separately and together: relationship to VKORC1 genotype.

  2013cites this paper